Compare BridgeBio Pharma Inc (BBIO) vs Howmet Aerospace Inc (HWM) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Howmet Aerospace (HWM) trades at $283.94, up 0.08% with strong bullish momentum following consecutive earnings beats. The stock shows robust fundamentals with Q2 2026 EPS of $1.33 beating estimates by 7.3%, driven by 24% revenue growth in aerospace and defense markets. Technical indicators signal bullish momentum with the current price above key support levels. The company raised full-year 2026 guidance, reflecting confidence in continued demand across commercial aerospace and gas turbine segments.

Outlook remains positive with 84% analyst buy ratings and $334.63 consensus price target suggesting 18% upside. Key risks include execution of capacity expansion plans and potential supply chain constraints. The combination of strong earnings momentum, raised guidance, and institutional support positions HWM for continued growth, though investors should monitor Q3 2026 results due for confirmation of guidance sustainability.